Richmond Pharmacology: Difference between revisions

Content deleted Content added

Inline

Revision as of 12:46, 4 August 2015

Richmond Pharmacology Ltd is a privately held contract research organisation based at St George’s University of London and Croydon University Hospital. The main activity is the early clinical development of new medicines and devices on behalf of bio-pharmaceutical companies. The company has a strong global reach with more than 70% of its revenues originating from overseas sponsors. Revenues used to either directly or indirectly fund and promote academic research and the company performs pure academic studies as well as commercially sponsored clinical trials.

Richmond Pharmacology Ltd is one of 14 MHRA accredited Phase I Units in the UK and maintains a large community of over 200,000 healthy and patient individuals interested in participating in clinical trials.

Publications by Richmond Pharmacology Ltd fall into three main categories: Publication of industry sponsors clinical trials ^[1] ^[2] ^[3] ^[4] ^[5], methodological papers aimed at disseminating techniques for clinical trial design and conduct ^[6] ^[7] ^[8] ^[9] ^[10] ^[11] and original research primarily concerned with sudden cardiac death in diabetes ^[12].

References

^ Sakurai Y, Nishimura A, Kennedy G, Hibberd M, Jenkins R, Okamoto H, Yoneyama T, Jenkins H, Ashida K, Irie S, Täubel J. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. Clin Transl Gastroenterol. 2015 25;6:e94. (http://www.nature.com/ctg/journal/v6/n6/pdf/ctg201518a.pdf)
^ Täubel J, Lorch U, Rossignol JF, Ferber G, John Camm A. Analyzing the relationship of QT interval and exposure to Nitazoxanide, a prospective candidate for influenza antiviral therapy-A formal TQT study. J Clin Pharmacol. 2014, 54(9): 987–994 (http://onlinelibrary.wiley.com/doi/10.1002/jcph.300/abstract)
^ Wolf C, Sidhu J, Otoul C, Morris D, Cnops J, Taubel J, Bennett B. Pharmacodynamic consequences of administration of the VLA-4 antagonist CDP323 in subjects with multiple sclerosis: a randomized, double-blind phase 1/2 study PLoS One. 2013; 8(3): e58438 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589412/pdf/pone.0058438.pdf)
^ Taubel J, Naseem A, Wang D, Arezina R, Lorch U, Camm A. J. Repeated dosing of strontium ranelate 4g over 15 days does not prolong QTc interval in healthy volunteers. Br J Clin Pharmacol 2012, 74(2): 296-303 (http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2012.04190.x/epdf)
^ Naseem A, Harada T, Wang D, Arezina R, Lorch U, Onel E, Camm AJ, Taubel J. Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers. J. Clin. Pharmacol. 2012, 52(9): 1441-1447 (http://onlinelibrary.wiley.com/doi/10.1177/0091270011419853/abstract)
^ Ferber G, Lorch U, Taubel J. The Power of Phase I Studies to Detect Clinical Relevant QTc Prolongation: A Resampling Simulation Study. BioMed Research International 2015, Article ID 293564, in press. (http://www.hindawi.com/journals/bmri/aa/293564/)
^ Taubel J, Ferber G. The reproducibility of QTc changes after meal intake. Journal of Electrocardiology 2015, 48(2): 274–275 (http://www.jecgonline.com/article/S0022-0736(14)00445-2/pdf)
^ Ferber G, Wang D, Taubel J. Concentration-effect modelling based on change from baseline to assess the prolonging effect of drugs on QTc together with an estimate of the circadian time course. The Journal of Clinical Pharmacology 2014, 54(12):1400-1406 (http://onlinelibrary.wiley.com/doi/10.1002/jcph.347/abstract;jsessionid=EA58985C1C8BAA3856963DFB1F54B88C.f04t04)
^ Taubel J, Wong A, Naseem A, Ferber G, Camm A. J. Shortening of the QT interval after food can be used to demonstrate assay sensitivity in thorough QT studies. J Clin Pharmacol 2012;52 1558-1565 (http://www.ncbi.nlm.nih.gov/pubmed/22067197)
^ Lorch U, O’Kane M, Taubel J. Three steps to writing adaptive study protocols in the early phase clinical development of new medicines. BMC Medical Research Methodology 2014, 14:84. (http://www.biomedcentral.com/1471-2288/14/84)
^ Lorch U, Berelowitz K, Ozen C, Naseem A, Akuffo E, Taubel J. The practical application of adaptive study design in early phase clinical trials: a retrospective analysis of time savings. Lorch et al. Eur J Clin Pharmacol 2012, 68:543–551 (http://link.springer.com/article/10.1007%2Fs00228-011-1176-3)
^ Taubel J, Lorch U, Ferber G, Singh J, Batchvarov V, Savelieva I, Camm A. J. Insulin at normal physiological levels does not prolong QTc interval in thorough QT studies performed in healthy volunteers. British Journal of Clinical Pharmacology 2012, 75(2):392–403 (http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2012.04376.x/epdf)

External links

[1] Sakurai Y, Nishimura A, Kennedy G, Hibberd M, Jenkins R, Okamoto H, Yoneyama T, Jenkins H, Ashida K, Irie S, Täubel J. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. Clin Transl Gastroenterol. 2015 25;6:e94. (http://www.nature.com/ctg/journal/v6/n6/pdf/ctg201518a.pdf)

[2] Täubel J, Lorch U, Rossignol JF, Ferber G, John Camm A. Analyzing the relationship of QT interval and exposure to Nitazoxanide, a prospective candidate for influenza antiviral therapy-A formal TQT study. J Clin Pharmacol. 2014, 54(9): 987–994 (http://onlinelibrary.wiley.com/doi/10.1002/jcph.300/abstract)

[3] Wolf C, Sidhu J, Otoul C, Morris D, Cnops J, Taubel J, Bennett B. Pharmacodynamic consequences of administration of the VLA-4 antagonist CDP323 in subjects with multiple sclerosis: a randomized, double-blind phase 1/2 study PLoS One. 2013; 8(3): e58438 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589412/pdf/pone.0058438.pdf)

[4] Taubel J, Naseem A, Wang D, Arezina R, Lorch U, Camm A. J. Repeated dosing of strontium ranelate 4g over 15 days does not prolong QTc interval in healthy volunteers. Br J Clin Pharmacol 2012, 74(2): 296-303 (http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2012.04190.x/epdf)

[5] Naseem A, Harada T, Wang D, Arezina R, Lorch U, Onel E, Camm AJ, Taubel J. Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers. J. Clin. Pharmacol. 2012, 52(9): 1441-1447 (http://onlinelibrary.wiley.com/doi/10.1177/0091270011419853/abstract)

[6] Ferber G, Lorch U, Taubel J. The Power of Phase I Studies to Detect Clinical Relevant QTc Prolongation: A Resampling Simulation Study. BioMed Research International 2015, Article ID 293564, in press. (http://www.hindawi.com/journals/bmri/aa/293564/)

[7] Taubel J, Ferber G. The reproducibility of QTc changes after meal intake. Journal of Electrocardiology 2015, 48(2): 274–275 (http://www.jecgonline.com/article/S0022-0736(14)00445-2/pdf)

[8] Ferber G, Wang D, Taubel J. Concentration-effect modelling based on change from baseline to assess the prolonging effect of drugs on QTc together with an estimate of the circadian time course. The Journal of Clinical Pharmacology 2014, 54(12):1400-1406 (http://onlinelibrary.wiley.com/doi/10.1002/jcph.347/abstract;jsessionid=EA58985C1C8BAA3856963DFB1F54B88C.f04t04)

[9] Taubel J, Wong A, Naseem A, Ferber G, Camm A. J. Shortening of the QT interval after food can be used to demonstrate assay sensitivity in thorough QT studies. J Clin Pharmacol 2012;52 1558-1565 (http://www.ncbi.nlm.nih.gov/pubmed/22067197)

[10] Lorch U, O’Kane M, Taubel J. Three steps to writing adaptive study protocols in the early phase clinical development of new medicines. BMC Medical Research Methodology 2014, 14:84. (http://www.biomedcentral.com/1471-2288/14/84)

[11] Lorch U, Berelowitz K, Ozen C, Naseem A, Akuffo E, Taubel J. The practical application of adaptive study design in early phase clinical trials: a retrospective analysis of time savings. Lorch et al. Eur J Clin Pharmacol 2012, 68:543–551 (http://link.springer.com/article/10.1007%2Fs00228-011-1176-3)

[12] Taubel J, Lorch U, Ferber G, Singh J, Batchvarov V, Savelieva I, Camm A. J. Insulin at normal physiological levels does not prolong QTc interval in thorough QT studies performed in healthy volunteers. British Journal of Clinical Pharmacology 2012, 75(2):392–403 (http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2012.04376.x/epdf)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

Revision as of 12:21, 4 August 2015 edit Swelgemoed (talk \| contribs) 129 edits No edit summary ← Previous edit		Revision as of 12:46, 4 August 2015 edit undo Seagull123 (talk \| contribs) Extended confirmed users 9,671 edits Removed speedy delete tag as according to the tag it is a copy of itself Next edit →
Line 1:		Line 1:

	{{db-a10\|article=Richmond Pharmacology}}
	'''Richmond Pharmacology Ltd''' is a privately held contract research organisation based at '''[https://www.stgeorges.nhs.uk/ St George’s University of London]''' and [http://www.croydonhealthservices.nhs.uk/patients-visitors/Croydon-University-Hospital.htm '''Croydon University Hospital''']. The main activity is the early clinical development of new medicines and devices on behalf of bio-pharmaceutical companies. The company has a strong global reach with more than 70% of its revenues originating from overseas sponsors. [https://www.researchgate.net/profile/Jorg_Taubel Revenues used to either directly or indirectly fund and promote academic research] and the company performs pure academic studies as well as commercially sponsored clinical trials.		'''Richmond Pharmacology Ltd''' is a privately held contract research organisation based at '''[https://www.stgeorges.nhs.uk/ St George’s University of London]''' and [http://www.croydonhealthservices.nhs.uk/patients-visitors/Croydon-University-Hospital.htm '''Croydon University Hospital''']. The main activity is the early clinical development of new medicines and devices on behalf of bio-pharmaceutical companies. The company has a strong global reach with more than 70% of its revenues originating from overseas sponsors. [https://www.researchgate.net/profile/Jorg_Taubel Revenues used to either directly or indirectly fund and promote academic research] and the company performs pure academic studies as well as commercially sponsored clinical trials.